CAHR2014 - Day 2 - Special Session: Canadian HIV Vaccine Initiative -- Vaccine Research Plenary

The Role of Vaccines in HIV Prevention Strategies

HIV Prevention Research Landscape: Putting HIV Vaccine Trials in Context

Learning Objectives:

To review combination prevention for HIV including biomedical, behavioural, and structural elements to address immediate risks, underlying vulnerabilities, and the pathways that link them;

To update information on current and planned HIV prevention research, including antiretroviral drugs that reduce the risk of HIV acquisition and onward HIV transmission; and

To determine when voluntary medical male circumcision or pre-exposure prophylaxis should be part of the standard of prevention offered to all arms of an HIV vaccine trial.


An HIV Vaccine Will Be Needed to Bring the HIV Pandemic to Zero

Learning Objectives:

To review mathematical modelling done by UNAIDS suggesting that the full scale-up of existing HIV preventive intervention in developing countries may be able to reduce annual HIV infections to around 548,000 by 2050 (from the current annual estimate of 2.3 million). However that effort would cost approximately 23 billion dollars annually (from the current investment of 17 billion dollars per year). Will donors and developing countries assume those expenses?;

To review mathematical model estimating that adding a 60% effective preventive vaccine around 2025 would reduce the annual incidence to around 120,000 by 2050;

To understand that bringing the AIDS pandemic to zero will need a rational combination of existing and new interventions (such as vaccines), tailored to the needs of different affected populations; and

To discuss the current effort required to develop a much needed HIV vaccine.